Results 181 to 190 of about 1,291,194 (313)

Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients. [PDF]

iScience
González-Rodríguez L, Martí-Antonio M, Mota-Zamorano S, Chicharro C, Cancho B, Álvarez Á, Verde Z, Fernández-Araque A, Bandrés F, Robles NR, Gervasini G.   +10 more
europepmc   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associations with lipid metabolism and early onset. [PDF]

J Neurol
Díaz-Belloso R, Martín-Bornez M, Macías-García D, García-Díaz S, Bonilla-Toribio M, Buiza-Rueda D, Sánchez RP, Muñoz-Delgado L, Ojeda E, Jesús S, Adarmes-Gómez A, Carrillo F, Mir P, Gómez-Garre P.   +13 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Molecular epidemiological and genetic variability of <i>Salmonella</i> isolates from the tropical mountainous region of southern China (2017-2024). [PDF]

Microbiol Spectr
Su L, Lun H, Li N, Xian X, Li B, Liang Y, Jibril AH, Jian M, Xu G, Huang G, Liu Z, Huang K.   +11 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Genetic variability in almond (Prunus dulcis L.) in South Türkiye: morphological, biochemical, and SSR analyses. [PDF]

BMC Plant Biol
Bayazıt S, Çalışkan O, Coşkun ÖF, Yaman M.   +3 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Sweet Taste Receptors' Genetic Variability in Advanced Potential Targets of Obesity. [PDF]

Nutrients
Wagner-Reguero S, Fernández LP, Colmenarejo G, Cruz-Gil S, Espinosa I, Molina S, Crespo MC, Aguilar-Aguilar E, Marcos-Pasero H, de la Iglesia R, Loria-Kohen V, Ruiz RR, Laparra-Llopis M, de Molina AR, Gómez de Cedrón M.   +14 more
europepmc   +1 more source